Pharma Marketing Company Investment Opportunity in Germany
Specialised wholesaler of prescription drugs in Germany having 80 clients.
This transaction has concluded.
Premium Plan
| Established | 50-60 year(s) |
| Employees | 100 - 500 |
| Legal Entity | Limited Liability Company (LLC) |
| Reported Sales | USD 43 million |
| Run Rate Sales | USD 47 million |
| EBITDA Margin | 15 % |
| Industries | Pharma Marketing |
| Locations | Germany |
| Local Time | 11:05 AM Europe / Berlin |
| Listed By | Advisor / Business Broker |
| Status | Active |
Partial Stake Sale
USD
11 million
for
85.0%
stake
(Native Currency: EUR 10,000,000)
Reason: For growth. Willing to give ownership stake.
Includes physical assets worth
USD
21 million
Business Overview
- Business is a specialised wholesaler for prescription drugs, based in Germany that started operations in 1970.
- Cater to the B2B market and have 80 clients.
- This is a highly regulated market.
- Business has potential to expand into the medical cannabis market.
- Annual sales growth of 10% and steady EBITDA of 15%.
- Physical assets include stock.
Products & Services Overview
Specialised wholesaler for prescription drugs, potential to expand into the medical cannabis market.
Facilities Overview
Have a rented property. More information after NDA.
Capitalization Overview
Not Disclosed
Recent Activity
-
Earlier than 15 daysPartner, Mumbai, M&A Advisor connected with the Business
-
Earlier than 15 daysIndependent Investor, Manufacturing And Technology, Singapore, Individual Investor / Buyer connected with the Business
-
Earlier than 15 daysBusiness Analyst, Kiev, M&A Advisor connected with the Business
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
